PLIANT THERAPEUTICS FILES 8-K FOR UNSPECIFIED 'OTHER EVENT'
Ticker: PLRX · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: other-event, corporate-filing, disclosure
TL;DR
**PLRX filed an 8-K for an 'Other Event' on Feb 4, details pending, watch for impact.**
AI Summary
Pliant Therapeutics, Inc. filed an 8-K on February 5, 2024, reporting an "Other Event" that occurred on February 4, 2024. This filing indicates a significant, but unspecified, development that the company deemed important enough to disclose immediately. For investors, this matters because such an event could signal anything from a new drug trial milestone to a change in corporate strategy, potentially impacting the stock's future performance, though the specific details are not yet public.
Why It Matters
This filing signals an important, undisclosed event for Pliant Therapeutics, Inc. that could influence its stock price once details are revealed. Investors should monitor for further announcements to understand the nature and impact of this event.
Risk Assessment
Risk Level: medium — The risk is medium because an unspecified 'Other Event' could be positive or negative, creating uncertainty for investors until more information is disclosed.
Analyst Insight
A smart investor would hold off on making significant decisions regarding PLRX until the specific details of the 'Other Event' are disclosed, as the impact could be either positive or negative.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — the registrant filing the 8-K
- February 4, 2024 (date) — date of the earliest event reported
- February 5, 2024 (date) — date the 8-K was filed
- 001-39303 (other) — Commission File Number for PLIANT THERAPEUTICS, INC.
- PLRX (other) — trading symbol for Common Stock on Nasdaq
FAQ
What is the specific nature of the 'Other Event' reported by Pliant Therapeutics, Inc. on February 4, 2024?
The 8-K filing, specifically under 'ITEM INFORMATION: Other Events', does not disclose the specific nature of the event. It only states that an 'Other Event' occurred on February 4, 2024, which is the 'Date of earliest event reported'.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted to the SEC on February 5, 2024, as indicated by the 'FILED AS OF DATE: 20240205'.
What is the trading symbol and exchange for Pliant Therapeutics, Inc.'s common stock?
Pliant Therapeutics, Inc.'s common stock trades under the symbol 'PLRX' on 'The Nasdaq Stock Market LLC', as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address of Pliant Therapeutics, Inc.?
The business address of Pliant Therapeutics, Inc. is '260 Littlefield Avenue, South San Francisco, CA 94080', as listed under 'BUSINESS ADDRESS'.
Does this 8-K filing indicate that Pliant Therapeutics, Inc. is an emerging growth company?
The filing includes a checkbox section to 'Indicate by check mark whether the registrant is an emerging growth company', but none of the boxes are checked, nor is there any explicit statement confirming or denying its status as an emerging growth company in the provided text.
Filing Stats: 657 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-02-05 07:31:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Mar
Filing Documents
- d734141d8k.htm (8-K) — 25KB
- d734141dex991.htm (EX-99.1) — 27KB
- g734141dsp010.jpg (GRAPHIC) — 37KB
- g734141g0205032634008.jpg (GRAPHIC) — 2KB
- 0001193125-24-023459.txt ( ) — 232KB
- plrx-20240204.xsd (EX-101.SCH) — 3KB
- plrx-20240204_lab.xml (EX-101.LAB) — 17KB
- plrx-20240204_pre.xml (EX-101.PRE) — 11KB
- d734141d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 4, 2024, titled "Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: February 5, 2024 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer